Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study
Arthritis & Rheumatism2008Vol. 58(10), pp. 2968–2980
Citations Over TimeTop 1% of 2008 papers
Mark C. Genovese, James D. McKay, Е. Л. Насонов, Eduardo Mysler, Nilzio A Da Silva, Emma Alecock, Thasia Woodworth, Juan J. Gómez‐Reino
Abstract
Tocilizumab combined with any of the DMARDs evaluated was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents.
Related Papers
- → Tocilizumab for treating juvenile idiopathic arthritis(2016)27 cited
- → OA31 Real life experience of tocilizumab treatment for giant cell arteritis(2023)1 cited
- → Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2(2020)
- → Outcome Comparison Between Tocilizumab Alone Vs Tocilizumab Followed by Intravenous Immunoglobulin (IVIG) Group in Critical COVID-19 Disease(2021)
- → Therapeutic effect of tocilizumab on inhibiting cytokine release syndrome in severe Coronavirus Disease 2019 patients(2022)